PMID- 29679417
OWN - NLM
STAT- MEDLINE
DCOM- 20190812
LR  - 20230928
IS  - 1531-8249 (Electronic)
IS  - 0364-5134 (Print)
IS  - 0364-5134 (Linking)
VI  - 83
IP  - 6
DP  - 2018 Jun
TI  - A probiotic modulates the microbiome and immunity in multiple sclerosis.
PG  - 1147-1161
LID - 10.1002/ana.25244 [doi]
AB  - OBJECTIVE: Effect of a probiotic on the gut microbiome and peripheral immune 
      function in healthy controls and relapsing-remitting multiple sclerosis (MS) 
      patients. METHODS: MS patients (N = 9) and controls (N = 13) were orally 
      administered a probiotic containing Lactobacillus, Bifidobacterium, and 
      Streptococcus twice-daily for two months. Blood and stool specimens were 
      collected at baseline, after completion of the 2-month treatment, and 3 months 
      after discontinuation of therapy. Frozen peripheral blood mononuclear cells 
      (PBMCs) were used for immune cell profiling. Stool samples were used for 16S rRNA 
      profiling and metabolomics. RESULTS: Probiotic administration increased the 
      abundance of several taxa known to be depleted in MS such as Lactobacillus. We 
      found that probiotic use decreased the abundance of taxa previously associated 
      with dysbiosis in MS, including Akkermansia and Blautia. Predictive metagenomic 
      analysis revealed a decrease in the abundance of several KEGG (Kyoto Encyclopedia 
      of Genes and Genomes) pathways associated with altered gut microbiota function in 
      MS patients, such as methane metabolism, following probiotic supplementation. At 
      the immune level, probiotic administration induced an anti-inflammatory 
      peripheral immune response characterized by decreased frequency of inflammatory 
      monocytes, decreased mean fluorescence intensity (MFI) of CD80 on classical 
      monocytes, as well as decreased human leukocyte antigen (HLA) D related MFI on 
      dendritic cells. Probiotic administration was also associated with decreased 
      expression of MS risk allele HLA-DQA1 in controls. Probiotic-induced increase in 
      abundance of Lactobacillus and Bifidobacterium was associated with decreased 
      expression of MS risk allele HLA.DPB1 in controls. INTERPRETATION: Our results 
      suggest that probiotics could have a synergistic effect with current MS 
      therapies. Ann Neurol 2018.
CI  - (c) 2018 American Neurological Association.
FAU - Tankou, Stephanie K
AU  - Tankou SK
AD  - Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, 
      Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 
      Boston, Massachusetts 02115, USA.
AD  - Evergrande Center for Immunologic Diseases.
FAU - Regev, Keren
AU  - Regev K
AD  - Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, 
      Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 
      Boston, Massachusetts 02115, USA.
FAU - Healy, Brian C
AU  - Healy BC
AD  - Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, 
      Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 
      Boston, Massachusetts 02115, USA.
FAU - Tjon, Emily
AU  - Tjon E
AD  - Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, 
      Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 
      Boston, Massachusetts 02115, USA.
AD  - Evergrande Center for Immunologic Diseases.
FAU - Laghi, Luca
AU  - Laghi L
AD  - University of Bologna, Department of Agricultural and Food Sciences, Cesena 
      47521, Italy.
FAU - Cox, Laura M
AU  - Cox LM
AD  - Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, 
      Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 
      Boston, Massachusetts 02115, USA.
AD  - Evergrande Center for Immunologic Diseases.
FAU - Kivisakk, Pia
AU  - Kivisakk P
AD  - Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, 
      Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 
      Boston, Massachusetts 02115, USA.
AD  - Evergrande Center for Immunologic Diseases.
FAU - Pierre, Isabelle V
AU  - Pierre IV
AD  - Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, 
      Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 
      Boston, Massachusetts 02115, USA.
AD  - Evergrande Center for Immunologic Diseases.
FAU - Hrishikesh, Lokhande
AU  - Hrishikesh L
AD  - Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, 
      Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 
      Boston, Massachusetts 02115, USA.
FAU - Gandhi, Roopali
AU  - Gandhi R
AD  - Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, 
      Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 
      Boston, Massachusetts 02115, USA.
AD  - Evergrande Center for Immunologic Diseases.
FAU - Cook, Sandra
AU  - Cook S
AD  - Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, 
      Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 
      Boston, Massachusetts 02115, USA.
FAU - Glanz, Bonnie
AU  - Glanz B
AD  - Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, 
      Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 
      Boston, Massachusetts 02115, USA.
FAU - Stankiewicz, James
AU  - Stankiewicz J
AD  - Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, 
      Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 
      Boston, Massachusetts 02115, USA.
FAU - Weiner, Howard L
AU  - Weiner HL
AD  - Ann Romney Center for Neurologic Diseases, Partners Multiple Sclerosis Center, 
      Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 
      Boston, Massachusetts 02115, USA.
AD  - Evergrande Center for Immunologic Diseases.
LA  - eng
GR  - R01 NS087226/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180608
PL  - United States
TA  - Ann Neurol
JT  - Annals of neurology
JID - 7707449
RN  - 0 (RNA, Ribosomal, 16S)
MH  - Adult
MH  - Bifidobacterium/genetics/*immunology
MH  - Female
MH  - Gastrointestinal Microbiome/physiology
MH  - Humans
MH  - Lactobacillus/genetics/immunology
MH  - Leukocytes, Mononuclear/metabolism
MH  - Male
MH  - Microbiota/genetics/*immunology
MH  - Middle Aged
MH  - Multiple Sclerosis/*genetics/immunology
MH  - Probiotics/*metabolism
MH  - RNA, Ribosomal, 16S/genetics
MH  - Young Adult
PMC - PMC6181139
MID - NIHMS975663
COIS- Potential Conflicts of Interest: This study was supported in part by Teva 
      Neuroscience (Teva manufactures the drug glatiramer acetate used in this study).
EDAT- 2018/04/22 06:00
MHDA- 2019/08/14 06:00
PMCR- 2018/10/11
CRDT- 2018/04/22 06:00
PHST- 2017/11/13 00:00 [received]
PHST- 2018/04/16 00:00 [revised]
PHST- 2018/04/18 00:00 [accepted]
PHST- 2018/04/22 06:00 [pubmed]
PHST- 2019/08/14 06:00 [medline]
PHST- 2018/04/22 06:00 [entrez]
PHST- 2018/10/11 00:00 [pmc-release]
AID - 10.1002/ana.25244 [doi]
PST - ppublish
SO  - Ann Neurol. 2018 Jun;83(6):1147-1161. doi: 10.1002/ana.25244. Epub 2018 Jun 8.